Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways

Author(s): Siew Ching Ngai*

Journal Name: Current Drug Targets

Volume 21 , Issue 9 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a natural protein expressed in a wide range of tissues in our body. It is a promising anti-cancer agent due to its selective killing of cancer cells, rendering normal cells unharmed. However, resistance occurs either intrinsically or develops over the course of TRAIL treatment. In view of its specificity to cancer cells, there is a pushing need to overcome TRAIL resistance. Curcumin (Cur), a natural active constituent of turmeric, has been evidenced to have anti-cancer properties. However, it is limited by its sparing solubility and low bioavailability. Combinational therapy is one of the most frequently used strategies to overcome these limitations, which has been proved to be more effective than monotherapy by achieving synergistic effects and reducing toxicity. This review aims to discuss TRAIL and its underlying apoptotic mechanisms, the combinational treatment of Cur and TRAIL in view of their respective limitations, and the underlying apoptotic mechanisms activated by the sensitization of cancers by Cur towards TRAIL-induced apoptosis. Finally, this review discusses the research gap and the author’s insight into this research area in bridging the research gap from bench to bedside.

Keywords: Curcumin, TRAIL, sensitization, cancers, extrinsic apoptotic pathway, intrinsic apoptotic pathway.

[1]
Yagawa Y, Tanigawa K, Kobayashi Y, Yamamoto M. Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. J Cancer Metastasis Treat 2017; 3: 218-30.
[http://dx.doi.org/10.20517/2394-4722.2017.35]
[2]
Baudino TA. Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol 2015; 12(1): 3-20.
[http://dx.doi.org/10.2174/1570163812666150602144310] [PMID: 26033233]
[3]
Aldeghaither DS, Zahavi DJ, Murray JC, et al. A Mechanism of resistance to antibody-targeted immune attack. Cancer Immunol Res 2019; 7(2): 230-43.
[http://dx.doi.org/10.1158/2326-6066.CIR-18-0266] [PMID: 30563830]
[4]
Fakiruddin KS, Ghazalli N, Lim MN, Zakaria Z, Abdullah S. Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour. Int J Mol Sci 2018; 19(8): 2188.
[http://dx.doi.org/10.3390/ijms19082188] [PMID: 30060445]
[5]
Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005; 15(6): 430-8.
[http://dx.doi.org/10.1038/sj.cr.7290311] [PMID: 15987601]
[6]
Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 2004; 172(1): 123-9.
[http://dx.doi.org/10.4049/jimmunol.172.1.123] [PMID: 14688317]
[7]
Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4(2): 232-4.
[http://dx.doi.org/10.1038/nm0298-232] [PMID: 9461199]
[8]
Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39(7-8): 1462-75.
[http://dx.doi.org/10.1016/j.biocel.2007.02.007] [PMID: 17403612]
[9]
Wong SHM, Kong WY, Fang C-M, et al. The TRAIL to cancer therapy: Hindrances and potential solutions. Crit Rev Oncol Hematol 2019; 143: 81-94.
[http://dx.doi.org/10.1016/j.critrevonc.2019.08.008] [PMID: 31561055]
[10]
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2(6): 420-30.
[http://dx.doi.org/10.1038/nrc821] [PMID: 12189384]
[11]
Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27(48): 6207-15.
[http://dx.doi.org/10.1038/onc.2008.298] [PMID: 18931688]
[12]
Kong WY, Yee ZY, Mai CW, Fang C-M, Abdullah S, Ngai SC. Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis. Heliyon 2019; 5(9)e02468
[http://dx.doi.org/10.1016/j.heliyon.2019.e02468] [PMID: 31687564]
[13]
Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5(11): 897-907.
[http://dx.doi.org/10.1038/nrm1496] [PMID: 15520809]
[14]
Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21(9): 1350-64.
[http://dx.doi.org/10.1038/cdd.2014.81] [PMID: 24948009]
[15]
Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8(10): 782-98.
[http://dx.doi.org/10.1038/nrc2465] [PMID: 18813321]
[16]
Trivedi R, Mishra DP. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol 2015; 5: 69.
[http://dx.doi.org/10.3389/fonc.2015.00069] [PMID: 25883904]
[17]
Jost PJ, Grabow S, Gray D, et al. XIAP acts as a switch between type I and type II FAS-induced apoptosis signalling. Nature 2009; 460(7258): 1035-9.
[http://dx.doi.org/10.1038/nature08229] [PMID: 19626005]
[18]
Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108(2): 153-64.
[http://dx.doi.org/10.1016/S0092-8674(02)00625-6] [PMID: 11832206]
[19]
De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Lett 2016; 383(2): 250-60.
[http://dx.doi.org/10.1016/j.canlet.2016.10.005] [PMID: 27725224]
[20]
Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22(53): 8628-33.
[http://dx.doi.org/10.1038/sj.onc.1207232] [PMID: 14634624]
[21]
Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 2009; 7(11): 1835-44.
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0244] [PMID: 19843632]
[22]
Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32(11): 1341-50.
[http://dx.doi.org/10.1038/onc.2012.164] [PMID: 22580613]
[23]
Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11(1-2): 17-24.
[http://dx.doi.org/10.1016/j.drup.2008.02.001] [PMID: 18374623]
[24]
Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12(3): 228-37.
[http://dx.doi.org/10.1038/sj.cgt.7700792] [PMID: 15550937]
[25]
Yang X, Li Z, Wu Q, Chen S, Yi C, Gong C. TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors. Drug Deliv 2017; 24(1): 1526-36.
[http://dx.doi.org/10.1080/10717544.2017.1384863] [PMID: 28994313]
[26]
Hassan FU, Rehman MS, Khan MS, et al. Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. Front Genet 2019; 10: 514.
[http://dx.doi.org/10.3389/fgene.2019.00514] [PMID: 31214247]
[27]
Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in Treating Breast Cancer: A Review. J Lab Autom 2016; 21(6): 723-31.
[http://dx.doi.org/10.1177/2211068216655524] [PMID: 27325106]
[28]
Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res 2017; 36(1): 98.
[http://dx.doi.org/10.1186/s13046-017-0566-5] [PMID: 28724427]
[29]
Zaman MS, Chauhan N, Yallapu MM, et al. Curcumin nanoformulation for cervical cancer treatment. Sci Rep 2016; 6: 20051.
[http://dx.doi.org/10.1038/srep20051] [PMID: 26837852]
[30]
Salem M, Rohani S, Gillies ER. Curcumin, a promising anti-cancer therapeutic: a review of its chemical properties, bioactivity and approaches to cancer cell delivery. RSC Advances 2014; 4: 10815.
[http://dx.doi.org/10.1039/c3ra46396f]
[31]
Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G. New insights into therapeutic activity and anticancer properties of curcumin. J Exp Pharmacol 2017; 9: 31-45.
[http://dx.doi.org/10.2147/JEP.S70568] [PMID: 28435333]
[32]
Khazaei Koohpar Z, Entezari M, Movafagh A, Hashemi M. Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. Iran J Cancer Prev 2015; 8(3)e2331
[http://dx.doi.org/10.17795/ijcp2331] [PMID: 26413251]
[33]
Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002; 50(1): 46-52.
[http://dx.doi.org/10.1007/s00280-002-0465-z] [PMID: 12111111]
[34]
Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63(17): 5390-400.
[PMID: 14500373]
[35]
Park S, Cho DH, Andera L, Suh N, Kim I. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem 2013; 383(1-2): 39-48.
[http://dx.doi.org/10.1007/s11010-013-1752-1] [PMID: 23846485]
[36]
Iqbal B, Ghildiyal A, Sahabjada , et al. Antiproliferative and Apoptotic Effect of Curcumin and TRAIL (TNF Related Apoptosis inducing Ligand) in Chronic Myeloid Leukaemic Cells. J Clin Diagn Res 2016; 10(4): XC01-5.
[http://dx.doi.org/10.7860/JCDR/2016/18507.7579] [PMID: 27190933]
[37]
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30: 87.
[http://dx.doi.org/10.1186/1756-9966-30-87] [PMID: 21943236]
[38]
Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 2005; 26(11): 1905-13.
[http://dx.doi.org/10.1093/carcin/bgi167] [PMID: 15987718]
[39]
Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008; 7: 16.
[http://dx.doi.org/10.1186/1476-4598-7-16] [PMID: 18226269]
[40]
Deeb D, Jiang H, Gao X, et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 2004; 3(7): 803-12.
[PMID: 15252141]
[41]
Andrzejewski T, Deeb D, Gao X, et al. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol Res 2008; 17(6): 257-67.
[http://dx.doi.org/10.3727/096504008786991611] [PMID: 19192720]
[42]
Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 2007; 105(1): 104-12.
[http://dx.doi.org/10.1016/j.ygyno.2006.10.050] [PMID: 17174384]
[43]
Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA, Gautam SC. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 2005; 5(1): 39-48.
[PMID: 16416600]
[44]
Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013; 17(1): 61-75.
[http://dx.doi.org/10.1517/14728222.2013.733001] [PMID: 23173842]
[45]
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15(1): 49-63.
[http://dx.doi.org/10.1038/nrm3722] [PMID: 24355989]
[46]
Deeb D, Xu YX, Jiang H, et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003; 2(1): 95-103.
[PMID: 12533677]
[47]
Engesæter B Ø, Sathermugathevan M, Hellenes T, et al. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biology & Therapy. 2011; 12(1): 47-58.
[http://dx.doi.org/10.4161/cbt.12.1.15714]
[48]
Hussain AR, Siraj AK, Ahmed M, et al. XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer 2017; 17(1): 640.
[http://dx.doi.org/10.1186/s12885-017-3627-4] [PMID: 28893228]
[49]
Zhang Y, Zhu J, Tang Y, et al. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 2011; 6: 49.
[http://dx.doi.org/10.1186/1746-1596-6-49] [PMID: 21645409]
[50]
Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 2013; 4(9): 1349-64.
[http://dx.doi.org/10.18632/oncotarget.1174] [PMID: 23988408]
[51]
Jung EM, Park JW, Choi KS, et al. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 2006; 27(10): 2008-17.
[http://dx.doi.org/10.1093/carcin/bgl026] [PMID: 16613838]
[52]
Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008; 6(12): 1861-71.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0313] [PMID: 19074831]
[53]
Zhang Y, Yoshida T, Zhang B. TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther 2009; 8(10): 917-22.
[http://dx.doi.org/10.4161/cbt.8.10.8141] [PMID: 19270498]
[54]
Wong KE, Ngai SC, Chan K-G, Lee L-H, Goh B-H, Chuah L-H. Curcumin nanoformulations for colorectal cancer: A Review. Front Pharmacol 2019; 10: 152.
[http://dx.doi.org/10.3389/fphar.2019.00152] [PMID: 30890933]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 9
Year: 2020
Page: [849 - 854]
Pages: 6
DOI: 10.2174/1389450121666200302124426
Price: $65

Article Metrics

PDF: 16
HTML: 1